<span item_type="fundamental" item_id="618782fabc146f14254fe5ca0f1c1ce4" counter_id="ST/US/MAZE" env="prod"></span><span item_type="announcement" item_id="579903372055223169" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.66.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -35.84 M.</p><p></p><h3>Segment Revenue</h3><ul><li>License revenue for the three and nine months ended September 30, 2025, was $0, compared to $2.5 million and $167.5 million for the same periods in 2024, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Research and development expenses were $25.2 million for the three months ended September 30, 2025, compared to $19.9 million for the same period in 2024, and $80.9 million for the nine months ended September 30, 2025, compared to $61.3 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li><li>General and administrative expenses were $7.8 million for the three months ended September 30, 2025, compared to $6.9 million for the same period in 2024, and $24.0 million for the nine months ended September 30, 2025, compared to $18.9 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li><li>Net loss was $30.1 million for the three months ended September 30, 2025, compared to $24.8 million for the same period in 2024, and $96.6 million for the nine months ended September 30, 2025, compared to net income of $81.8 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $84.2 million for the nine months ended September 30, 2025, compared to net cash provided by operating activities of $98.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li><li>Net cash used in investing activities was - $67.6 million for the nine months ended September 30, 2025, compared to - $0.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li><li>Net cash provided by financing activities was $271.7 million for the nine months ended September 30, 2025, compared to $22.6 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>Maze Therapeutics, Inc. plans to initiate two Phase 2 proof-of-concept trials of MZE782 in 2026, evaluating plasma Phe reduction in phenylketonuria and proteinuria reduction in chronic kidney disease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li><li>The company expects to continue incurring significant expenses and increasing losses for the foreseeable future due to ongoing research and development activities, including clinical trials for lead programs MZE829 and MZE782.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li><li>As of September 30, 2025, Maze Therapeutics, Inc. had cash, cash equivalents, and marketable securities of $383.9 million, which is expected to fund operations for at least one year from the issuance date of the financial statements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842295/000119312525269689/maze-20250930.htm"></span></li></ul>

Maze Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0